Piper Sandler Maintains Overweight on Crinetics Pharmaceuticals, Raises Price Target to $97
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst Yasmeen Rahimi maintains an Overweight rating on Crinetics Pharmaceuticals (CRNX) and raises the price target from $56 to $97.
May 07, 2024 | 11:08 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Piper Sandler maintains an Overweight rating on Crinetics Pharmaceuticals and increases the price target to $97.
The upgrade in the price target by a reputable analyst like Yasmeen Rahimi from Piper Sandler is a strong positive signal to the market, indicating a bullish outlook on CRNX's future performance. This is likely to instill confidence among investors, potentially driving up the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100